Consensus Arcutis Biotherapeutics, Inc.

Stocks

ARQT

US03969K1088

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 27/10/2026 +04			5-day change	1st Jan Change
31.81 ^USD	+1.96%		-0.25%	+9.54%

10-09	Arcutis Biotherapeutics, Inc. Presents Data Across Its ZORYVE Portfolio at EADV and Fall Clinical Dermatology Conference	CI
10-09	Arcutis Biotherapeutics' Zoryve Shows Rapid Disease Clearance in Infant Atopic Dermatitis Trial	MT

Evolution of the Average Target: Arcutis Biotherapeutics, Inc.

Evolution of the Target Price: Arcutis Biotherapeutics, Inc.

Changes in Analyst Recommendations: Arcutis Biotherapeutics, Inc.

9ed670e1e.iAriri1dyUNhw0TcipqB7g-bI_eTgNjHRkPFFpmtpGQ.pWmF1H4Juyc-8xvv8sjenjfoSZnZ5bqKdAW1QP3MlxLvTYn0by-xDgCyHQ~edcaa1eb4aaa702cd8ef39c3897e875b

Analysts' recommendations: Arcutis Biotherapeutics, Inc.

11-04	Arcutis Biotherapeutics, Inc. Announces Publication of Positive Long-Term Safety and Efficacy Data of Zoryve®? (Roflumilast) Foam 0.3% in American Journal of Clinical Dermatology	CI
29/10/25	Morgan Stanley Raises Price Target on Arcutis Biotherapeutics to $32 From $21, Keeps Overweight Rating	MT
24/10/25	Arcutis to Present New Quality of Life and Long-Term Data with Zoryve®? (Roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatology Conference	CI
30/12/24	HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target	MT
28/08/24	Jefferies Initiates Arcutis Biotherapeutics at Buy	MT
15/05/24	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT
15/05/24	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating	MT
28/02/24	Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	MT
28/02/24	Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	MT
23/02/24	Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	MT
03/01/24	Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4	MT
13/11/23	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating	MT
08/11/23	JonesTrading Downgrades Arcutis Biotherapeutics to Hold From Buy	MT
06/11/23	Needham Adjusts Price Target on Arcutis Biotherapeutics to $8 From $22, Maintains Buy Rating	MT
27/10/23	Mizuho Downgrades Arcutis Biotherapeutics to Neutral From Buy	MT
13/10/23	Goldman Sachs Downgrades Arcutis Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $32	MT
26/05/23	Truist Securities Lowers Price Target on Arcutis Biotherapeutics to $40 From $45, Maintains Buy Rating	MT
11/05/23	Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating	MT
10/05/23	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $47, Maintains Overweight Rating	MT
10/05/23	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $57 From $61, Maintains Buy Rating	MT
12/04/23	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $47 From $50, Keeps Overweight Rating	MT
28/03/23	Truist Securities Lowers Arcutis Biotherapeutics' Price Target to $45 From $50, Maintains Buy Rating	MT
16/03/23	Needham Adjusts Price Target on Arcutis Biotherapeutics to $24 From $46, Maintains Buy Rating	MT
01/03/23	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $50 From $51, Maintains Overweight Rating	MT
13/12/22	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARCUTIS BIOTHERAPEUTICS, INC.					+23%
	ELI LILLY AND COMPANY					+4.27%
	JOHNSON & JOHNSON					+4.92%
	ABBVIE INC.					-0.68%
	ROCHE HOLDING AG					-2.56%
	MERCK & CO., INC.					+13.62%
	NOVARTIS AG					-2.85%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-10.64%
	GILEAD SCIENCES, INC.					+0.95%
	Average					+5.25%
	Weighted average by Cap.					+3.56%